Research programme: mRNA therapeutics - METiS Pharmaceuticals
Latest Information Update: 04 Jul 2025
At a glance
- Originator METiS Pharmaceuticals
- Class Antineoplastics; RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
- Research Autoimmune disorders
Most Recent Events
- 01 May 2025 mRNA therapeutics - Metis PHarmaceuticals is available for licensing as of 26 Jun 2025. https://www.metispharma.com/en/about
- 01 May 2025 Early research in Autoimmune disorders in China (unspecified route)
- 01 May 2025 Preclinical trials in Cancer in China (unspecified route)